All In Biotech

Drug Trial Radar · NCT06530849

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

A Phase 1/2 Clinical Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Actual

Start

Aug 22, 2024

Primary completion

Feb 1, 2027

Study completion Feb 1, 2027

Sponsor

Sponsor type
Industry
Collaborators
AstraZeneca; Suzhou Gracell Biotechnologies Co., Ltd.
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE).

Conditions

  • Refractory Systemic Lupus Erythematosus

Interventions

  • GC012F InjectionDrug

    GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT) rateTime frame: 28 days
  2. SLE Responder Index (SRI)-4 response rateTime frame: 48 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Shanghai, China

  • Research Site

    Wuhan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.